BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:MRT-2359 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of MRT-2359\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05546268-2661@assetmemo.bio
DTSTAMP:20261121T005812Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:MRT-2359: Phase 1/2 readout est. (NCT05546268)
DESCRIPTION:MRT-2359\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Stud
 y of Oral MRT-2359 in Selected Cancer Patients\nEstimated primary completi
 on: December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mr
 t-2359#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05546268
URL:https://assetmemo.bio/drug/mrt-2359#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07745361-2661@assetmemo.bio
DTSTAMP:20261121T005812Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:MRT-2359: Phase 2 readout est. (NCT07745361)
DESCRIPTION:MRT-2359\, phase 2\, Prostate Cancer.\nStudy: Study of Oral MRT
 -2359 With Apalutamide in Prostate Cancer\nEstimated primary completion: O
 ctober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mrt-2359
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077
 45361
URL:https://assetmemo.bio/drug/mrt-2359#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
